Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16952507 | 0.82 | — | — | |
| SCHEMBL2034789 | 0.76 | GAA (0.41) | TSHRALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL16791888 | 0.75 | KCNN4 (0.33) | TSHRALDH1A1KDM4E | |
| SCHEMBL134889 | 0.74 | KDM5A (0.36) | TSHRALDH1A1MEN1TP53CYP3A4 | |
| SCHEMBL4404035 | 0.73 | AR (0.36) | ALDH1A1MAPTSLC22A12PDK2KDM4E | |
| SCHEMBL16956643 | 0.73 | — | — | |
| SCHEMBL622920 | 0.73 | DDB1 (0.34) | ALDH1A1KDM4E | |
| SCHEMBL900817 | 0.73 | EPHX2 (0.32) | — | |
| SCHEMBL1068440 | 0.72 | HSD11B1 (0.33) | ALDH1A1TDP1SLC22A12 | |
| SCHEMBL4290700 | 0.72 | CYP1A2 (0.35) | TSHRALDH1A1CYP3A4SLC22A12PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759390-B2 | chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | claimed |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | claimed |
| EP-1966182-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071440-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-9585392-B2 | 3-phenylisoxazolin derivatives with herbicidal action | BAYER CROPSCIENCE AG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20150245615-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | BAYER CROPSCIENCE AG (DE) | 2015-09-03 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-7759390-B2 | chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | disclosed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | TSHR 1137/4885ALDH1A1 1383/4885MEN1 2393/4885 |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | TSHR 3036/4885ALDH1A1 1165/4885MEN1 2702/4885 |
| US-20150245615-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | CYP4X1, CBR3, PAOX | TSHR 1336/4885ALDH1A1 1019/4885MEN1 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.